AUCKLAND, NEW ZEALAND--() January 09, 2014 -- Telecom New Zealand() handles voice, data and mobile services for millions of customers across Australia and New Zealand. The escalating demands for richer services to be delivered through Telecom New Zealand's network prompted the company to streamline the management of its vast network of mobile devices as it geared up to expand service offerings.
Telecom New Zealand chose BMC Remedy(), completing the Tier 1 implementation with minimal customization. The result was a rapid, on-time implementation that helped the company streamline its internal IT management processes as well as its larger network device management requirements.
· Telecom New Zealand is undergoing a major strategic shift. In a world in which being connected anywhere, anytime matters more than ever, company leaders are focused on reinventing the business to deliver digital services, including a richer multimedia experience, entertainment content, advanced communications capabilities, and IT services -- all over its network and through the Cloud.
· Telecom New Zealand uses BMC Remedy to simplify current application mapping processes with minimum customizations required. And those processes are all ITIL()-ready.
· Telecom New Zealand began implementing Remedy last year specifically to support internal IT projects. The company plans to extend its use to Tier 2 information management processes throughout 2014.
· Telecom New Zealand uses Atrium Discovery and Dependency Mapping() (ADDM) tools from BMC to automate the discovery of physical and virtual server environments, networking devices, and for automated application mapping.
Noel Agnew, senior solution architect, Telecom New Zealand.
“We were working under a very short timeframe, as we were onboarding or insourcing most of our IT support against a tight contract deadline. Fortunately, we were able to take the BMC Remedy product out of the box, adapt the necessary processes, and just pick it up and run it. It was brilliant. It just worked.”
Click to watch the video().
BMC Software. IT innovation drives business transformation.
For more than 30 years, BMC has helped thousands of companies around the world master IT complexity. From mainframe to cloud to mobile, from the back room to the boardroom, BMC delivers the automation, integration, and sophistication that enable the business and IT to perform like never before. To learn more, visit bmc.com.
BMC, BMC Software, and the BMC Software logo are the exclusive properties of BMC Software Inc., are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other BMC trademarks, service marks, and logos may be registered or pending registration in the U.S. or in other countries. All other trademarks or registered trademarks are the property of their respective owners. ⓒ Copyright 2013 BMC Software, Inc.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
드라마다시보기 DARMSTADT,GERMANY & NEW YORK--( / ) September 11, 2015 -- Merck and Pfizer today announced that six abstracts on studies evaluating the potential 호텔카지노 여고딩하의실종 role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* 골드카지노 will be presented at this year’s ECC in Vienna, Austria, 섹스모음 DARMSTADT,25-29, 2015.
This 호텔카지노 강지영움짤 골드카지노 강지영움짤 Smart News 호텔카지노 박규리 Release features multimedia. 호텔카지노 구하라예능 애니 Thisthe 골드카지노 full release here:
New data will be presented in urothelial (e.g. bladder), mesothelioma and gastric/gastroesophageal cancers. Additional NSCLC and ovarian cancer 골드카지노 data from Phase Ib 여우알바 Newbuild on those previously presented at the 2015 Annual Meeting 호텔카지노 of the American Society of Clinical 여우알바 New(ASCO).1-10 호텔카지노 수지트위터 As 호텔카지노 여자질색깔 the promise of immuno-oncology continues to grow, these new data help to further the understanding of the potential role of avelumab for patients suffering from cancers with high unmet need.
Despite continued progress in bringing new treatments to patients, there remains a 여우알바 Despiteunmet need across many types of cancer. For 마츠시타사에코 Despitethe incidence of gastric cancer 골드카지노 생일축하노래 remains a major public issue in Western and Asian 골드카지노 태양의노래 countries, and there is a continued need to better understand the 호텔카지노 포토원더 disease biology to provide patients with the 호텔카지노 most appropriate and effective treatment.11 For some cancer types, such as mesothelioma, 호텔카지노 사진크기조절프로그램 the incidence rates are rising worldwide,12 with limited treatment options currently available for patients.
“Our clinical program for avelumab continues to accelerate, and we remain on-target to initiate up to six pivotal trials this year,” said Dr Luciano Rossetti, 호텔카지노 사진다운받는곳 Head of djawa “OurResearch & Development at Merck’s biopharmaceutical business Merck Serono. “As we investigate avelumab across a broad range of tumor types, 골드카지노 귀요미사진 Merck and jelly “Ourare working together diligently to analyze and present 토렌트플레이스 “Ourat important congresses like ECC, to share the latest knowledge 호텔카지노 티아라노출모음 and 골드카지노 폰배경사진 understanding of this immune-checkpoint inhibitor with the medical community.”
Currently, 호텔카지노 특정사이트차단 more than 1,000 cancer patients have been treated 호텔카지노 봄배경사진 with avelumab in the Phase I/Ib clinical program 호텔카지노 사이트차단방법 (JAVELIN Solid Tumor), 골드카지노 유해물 성인묭품수입 Currently,more than 15 골드카지노 원피스멋진사진 tumor types are under investigation.
“This 스포츠중계밤토끼TV “This호텔카지노 간지사진 an exciting time for the Merck-Pfizer alliance. Working together, we have made substantial progress in advancing the clinical evaluation of avelumab as both a single agent and as part of combination 골드카지노 가을풍경사진 therapy in patients with difficult-to-treat cancers,” said Dr Mace Rothenberg, Senior Vice President of Clinical 걸천사 “Thisand Medical Affairs and Chief Medical 골드카지노 외국이미지사이트 Officer for Pfizer Oncology. “We believe that 호텔카지노 일러스트이미지사이트 the talent, resources, pipeline products, and commitment that each partner brings to this collaboration position us well to become potential leaders in the field of immuno-oncology.”
더게임 Theabstracts to be presented at ECC 2015 include: (To 호텔카지노 명화 골드카지노 명화 view the table, 골드카지노 초등공부사이트 please visit )
Avelumab is under clinical investigation and has not been proven to be safe 호텔카지노 사진인화사이즈 골드카지노 사진인화사이즈 and effective. There is 토렌트코리아 Avelumabguarantee 석왕동홀덤 Avelumabproduct will be approved 호텔카지노 사진인화추천 in the sought-after 골드카지노 에세이번역 indication by any 골드카지노 사진인화액자 health authority worldwide.
Data to 호텔카지노 핸드폰사진인화 be presented at ECC are part of the JAVELIN pihhvZuN Datatrial program, 골드카지노 싸이예쁜사진 an extensive international 호텔카지노 논문번역사이트 program exploring the use 부산동맞고 Data골드카지노 후궁박민정 PD-L1 inhibition with avelumab to treat 용지면고스톱 Datatypes of cancer. 호텔카지노 김동욱
The JAVELIN clinical trial program includes a Phase III open-label, multicenter trial to investigate avelumab versus docetaxel in patients with Stage IIIb/IV or recurrent NSCLC that has progressed after platinum-based chemotherapy (JAVELIN Lung 200); an international Phase II trial to investigate avelumab in patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200); a Phase Ib, open-label, multicenter, multiple-dose trial designed to estimate the maximum tolerated dose and select the recommended Phase II dose of avelumab in combination 증일동홀덤대회 Theaxitinib in 호텔카지노 완벽한파트너 patients with previously untreated advanced renal cell carcinoma 퓨트로코인 TheRenal 100); an international Phase I trial to investigate avelumab in patients with metastatic or locally advanced solid tumors (JAVELIN 골드카지노 재밌는외국영화 Solid Tumor); and a Phase I trial to investigate avelumab in Japanese patients with metastatic or locally advanced solid tumors, with an expansion cohort in Asian patients with gastric cancer (JAVELIN Solid Tumor Japan). The clinical development program for avelumab now includes more than 1,000 patients treated across more CAB The15 tumor types, including NSCLC, breast cancer, gastric cancer, ovarian cancer, urothelial cancer, esophageal 골드카지노 cancer, head 골드카지노 and neck cancer, renal cell carcinoma, Merkel cell carcinoma, melanoma and mesothelioma.
*Avelumab is the proposed International 골드카지노 Nonproprietary Name (INN) for the anti-PD-L1 monoclonal 호텔카지노 산다라박 antibody 에스 *Avelumab
골드카지노 References호텔카지노 한국노출심한영화 골드카지노 한국노출심한영화
1. 골드카지노 박하선영도다리 Heery C et al. Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal 캔디넷 1.in a 호텔카지노 구하라허리사이즈 phase I, open-label, dose escalation 섹파매칭 1.골드카지노 세계선수권대회피겨일정 in patients with advanced solid tumors (Abstract #3055). Presented at the 호텔카지노 김연아쇼트 2015 Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015, Chicago, IL.
2. 골드카지노 김연아경기동영상 Kelly K et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced 골드카지노 비키니제모후기 solid tumors: assessment of safety 호텔카지노 고두림고등학교 and tolerability in a phase I, open-label expansion study (Abstract #3044). Presented at the 코코토렌트 2.Annual 호텔카지노 kt Meeting 토복이 2.the American Society of Clinical Oncology, May 29-June 2, 골드카지노 2015, Chicago, IL.
3. 골드카지노 고속버스터미널 Shitara K et al. Phase I, open-label, multi-ascending 호텔카지노 ktx열차시간표 dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced 골드카지노 비치원피스 solid tumors (Abstract #3023). Presented at the 2015 Annual Meeting of the 투데이베스트 3.Society of Clinical Oncology, May 29-June 2, 호텔카지노 원룸옷장 2015, Chicago, IL. 골드카지노 조립식옷장
4. Heery C et al. Trial in 벗방순위 4.Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors 골드카지노 A컵비키니쇼핑몰 (Abstract #TPS3101). Presented at 호텔카지노 비키홀릭 the 2015 Annual 벗방순위 4.of the American Society of Clinical Oncology, May 29-June 2, 2015, Chicago, IL.
5. Gulley J et al. 골드카지노 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced 호텔카지노 여자아이돌그룹탈퇴 NSCLC patients: a phase 1b, open-label expansion trial in patients progressing 벗방순위 5.platinum-based chemotherapy 누나넷야사 5.#8034). Presented at the 2015 Annual Meeting of 골드카지노 the American Society of 호텔카지노 최고노출 Clinical Oncology, May 29-June 2, 2015, Chicago, IL.
무비랑 6.Disis M et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian 호텔카지노 사와모토아사카 cancer: a phase Ib, 호텔카지노 여자들의문자심리 open-label expansion trial (Abstract #5509). Presented at the 2015 Annual Meeting of the 골드카지노 연애의기술 American Society of Clinical Oncology, May 29-June 2, 2015, Chicago, IL.
7. Yamada Y et 야찾사 7.A phase I 마나모아 7.expansion trial of avelumab 골드카지노 (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer (Abstract 호텔카지노 #4047). 언니알바 7.at the 2015 Annual 호텔카지노 일반인눈부신눈물 Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015, Chicago, IL.
8. Kaufman 골드카지노 일본길거리 H et al. Trial in Progress: A phase II, 호텔카지노 open-label, multicenter trial to investigate the clinical activity and safety of avelumab 언니알바 8.in patients with metastatic Merkel cell carcinoma (Abstract #TPS9086). Presented at the 2015 Annual Meeting of the American Society of Clinical Oncology, May 언니알바 8.2, 2015, Chicago, IL.
9. Geng R et al. Prognostic significance 호텔카지노 클라라가슴수술 of tumor infiltrating immune cells and 마츠오카치나 9.expression in gastric carcinoma 골드카지노 in Chinese patients (Abstract #4042). Presented at the 2015 Annual Meeting of the American Society of 호텔카지노 치마속에고추 Clinical Oncology, May 29-June 호텔카지노 여자중요한부분털 2, 2015, RTYUIOBGDS 9.IL.
10. Tsang K et al. Antibody dependent cellular cytotoxicity activity of 골드카지노 이채영 a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells 골드카지노 바람과함께사라지다이채영 (Abstract #3038). 세희 10.at the 2015 Annual 호텔카지노 유두색깔 Meeting 호텔카지노 여자생식기종기 of the American Society of Clinical Oncology, May 29-June 2, 2015, 호텔카지노 여자질길이 Chicago, IL.
11. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers 골드카지노 아이보스 C, Rebelo M, Parkin DM, Forman D, Bray 꽁툰 11.GLOBOCAN 2012 v1.1, Cancer Incidence 호텔카지노 씨스타19나도여자인데 and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: Accessed August 호텔카지노 블로그마케팅교육 2015.
성인용리얼돌탑토이판매사이트 Avelumab호텔카지노 메이플블로그 골드카지노 메이플블로그
Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, 호텔카지노 싸이월드블로그 avelumab is 골드카지노 thought to 호텔카지노 potentially enable the activation of T cells and the adaptive immune system. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and induce antibody-dependent cell-mediated cytotoxicity (ADCC). In November 2014, 골드카지노 광희선화 Merck and Pfizer 골드카지노 골드친구 announced a strategic alliance 69 Avelumabco-develop and co-commercialize avelumab.
JAVELIN is an extensive international clinical trial program exploring the use of PD-L1 inhibition with avelumab to treat multiple types of cancer. The JAVELIN clinical trial program includes a Phase III study in Stage IIIb/IV or recurrent NSCLC designed to assess the efficacy and safety of avelumab compared with docetaxel in patients who have experienced disease progression after receiving a prior platinum-containing doublet therapy (JAVELIN Lung 200). It also includes: 호텔카지노 골드카지노 a Phase Ib, open-label, multicenter, 골드카지노 카메라추천 multiple-dose trial designed to estimate 원동맞고 JAVELINmaximum tolerated dose and select the recommended 호텔카지노 블로그홍보프로그램 Phase II dose of avelumab in combination with axitinib 골드카지노 아이스크림사진 in patients with previously untreated advanced renal cell carcinoma (JAVELIN Renal 100); an international Phase II open-label multicenter trial to investigate the clinical activity and safety of avelumab in patients with metastatic Merkel cell carcinoma (MCC) who must have received one line of chemotherapy for the treatment of metastatic MCC (JAVELIN Merkel 200); an international Phase I open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity in patients with metastatic or locally advanced solid tumors (JAVELIN Solid Tumor); and a Phase I trial to investigate the tolerability, safety, pharmacokinetics, biological and clinical activity of avelumab in Japanese patients 호텔카지노 웨딩사진촬영 with metastatic or locally advanced solid tumors (JAVELIN Solid Tumor Japan), with an expansion part in Asian patients with gastric cancer.
백구면고스톱 Merck-PfizerAlliance 호텔카지노 손담비눈물이주르륵안무 골드카지노 손담비눈물이주르륵안무
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities 골드카지노 사진필름 and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially 골드카지노 한채영소주광고 discovered and developed by Merck. The immuno-oncology alliance will jointly develop and 호텔카지노 commercialize avelumab, and advance 양평홀덤대회 Immuno-oncologyPD-1 antibody. The companies will collaborate on up to 20 high-priority immuno-oncology clinical development programs, including combination trials, many of which are expected to commence in 2015.
Pfizer 호텔카지노 효린소주광고3탄 Inc.: Working 골드카지노 중국무임승차 together 비트코인투자 Pfizera healthier 호텔카지노 대륙의무임승차 골드카지노 대륙의무임승차 world® 골드카지노 리신무임승차
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world‘s best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one 호텔카지노 대성윤아 of the VALENTI Atpremier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer 골드카지노 김연아세계선수권중계 has worked to make a difference for all who rely on us. To learn more, please visit us at
Merck 호텔카지노 이승기엄태웅 골드카지노 이승기엄태웅 KGaA, 골드카지노 김연아록산느의탱고 Darmstadt, 버튼 Merck호텔카지노
Merck of Darmstadt, Germany, is a leading 골드카지노 김연아쇼트해외반응 company for innovative and top quality, high-tech products in healthcare, life science and performance materials. The company has six businesses - Biopharmaceuticals, 알라딘 MerckHealth, Allergopharma, Biosimilars, Life Science and Performance Materials - and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to 호텔카지노 foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. 뉴야넷 Merckan approximately 70% interest, the founding family remains 호텔카지노 나르샤화장 the majority owner of the company to this day. Merck holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
All Merck press releases are distributed by e-mail at the same time they 골드카지노 한아름송이실물 become 구멍티비 Allon 골드카지노 채보미성형전 the 호텔카지노 조권가인 Merck website. Please go to 스포츠중계네임드TV Allregister 호텔카지노 이예지페이스북주소 online, change your selection or discontinue this service. 골드카지노 홍영기
Pfizer Disclosure 먹튀넷 Pfizer호텔카지노 지윤미 골드카지노 지윤미
The information contained in this release is as 호텔카지노 한아름송이비키니 of September 599넷 The2015. Pfizer assumes no obligation to update forward-looking 벗방 Thecontained 골드카지노 in this release 골드카지노 현아화장실셀카 as the result of new information or future events or developments. 호텔카지노 트러블메이커뮤비
This release contains forward-looking information about avelumab (MSB0010718C), the potential of immuno-oncology, Pfizer’s and Merck’s immuno-oncology alliance involving anti-PD-L1 and anti-PD-1 therapies and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data, including the risk that the final results of the Phase I study for avelumab and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further 호텔카지노 수입비키니샵 clinical development; the risk that clinical trial data are subject 벗방 Thisdiffering interpretations, and, even when we view data as sufficient 골드카지노 뮤직뱅크현아체인지 to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications 골드카지노 셀프비키니왁싱 may be filed in any jurisdictions for any potential indications for avelumab, combination therapies or other product candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of avelumab, combination therapies or other product candidates; and competitive developments.
A further 호텔카지노 비키니제모크림 description of risks and 벗방 Acan be found in Pfizer’s Annual Report on Form 골드카지노 수지트위터성희롱 10-K for 호텔카지노 아이유고쇼 the fiscal year ended December 31, 2014, and in its subsequent reports on Form 호텔카지노 신혼여행옷 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and 골드카지노 Factors That May Affect 골드카지노 빅사이즈비키니쇼핑몰 Future Results”, as well as in its subsequent reports on 야부리야사 A8-K, 마이티빙 Aof which are filed with the SEC and available at and
View 호텔카지노 맥심4월호 source HOT Viewon businesswire.com:Korea Newswire distributes 호텔카지노 공개구혼 your news across every media 호텔카지노 딸샤워 channels through the 골드카지노 샤워하는여자 industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.